Form 4: Mirum Pharmaceuticals Director Equity Grant
Statement of Changes in Beneficial Ownership
Director Lon Cardon received an equity grant of stock options and restricted stock units from Mirum Pharmaceuticals.
Summary
- Director Lon Cardon was granted 3,772 stock options with an exercise price of $101.00.
- Director Lon Cardon was granted 1,980 restricted stock units (RSUs).
- Both the stock options and RSUs vest on the first anniversary of the grant date, or upon the 2027 annual stockholder meeting, whichever occurs first.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- The issuance of new equity instruments results in potential future dilution for existing shareholders.
Risks
- Market volatility affecting the value of the granted equity instruments.
- Potential for future dilution of common stock upon the exercise or vesting of these awards.
Future Outlook
The equity grants are subject to standard vesting schedules tied to the 2027 annual stockholder meeting or the first anniversary of the grant date.
Industry Context
StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise, aligning director compensation with long-term corporate performance.
Comparison to Industry Standards
- The use of a mix of stock options and RSUs is consistent with standard executive and director compensation packages in the mid-cap pharmaceutical industry.
- Vesting schedules tied to annual meetings are a common governance practice to ensure director retention through the annual cycle.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Lon Cardon authorized company officers to file SEC forms on his behalf. | 06/10/2026 | Standard administrative procedure to ensure timely regulatory compliance. |
Stakeholder Impact
- Shareholders may experience minor dilution upon the eventual exercise or vesting of these equity awards.
Next Steps
- Vesting of equity awards on the first anniversary of the grant date or the 2027 annual stockholder meeting.
Key Dates
| Date | Description |
|---|---|
| 06/10/2026 | Date of Power of Attorney execution. |
| 06/15/2026 | Date of the equity grant transaction. |
| 06/17/2026 | Filing date of the Form 4. |
| 06/14/2036 | Expiration date of the stock options. |
Keywords
MIRM, Mirum Pharmaceuticals, Form 4, Director Compensation, Equity Grant, Insider Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.